Developer docs
API playgroundTry for free, no card

Search company profiles

XBiotech

Full company profile

uuid00286mu

Namestring
XBiotech
Legal namestring
XBiotech USA, Inc.
Websiteurl
xbiotech.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

XBiotech (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company headquartered in Austin, Texas, founded in 2005 by John Simard to develop therapeutic antibodies derived directly from natural human immunity. Its True Human™ platform uses proprietary Super High Stringency Antibody Mining (SHSAM™) and genetic cloning technologies to identify rare, clinically relevant antibodies from blood donors — a position the company distinguishes from "humanized" or phage-display-derived antibodies — combined with a purpose-built, in-house single-use GMP bioreactor manufacturing facility (ISO Class 7/5 clean room) on a 48-acre Austin campus. The pipeline is centered on anti-IL-1α antibodies (vilamakitug in Phase II for axial spondyloarthritis; Natrunix in Phase II for rheumatoid arthritis and metastatic colorectal cancer via the TASKIN combination), plus Hutrukin (Phase I for stroke), Unmetix (anti-VZV + anti-IL-1α cocktail for shingles/PHN), and infectious-disease candidates targeting influenza, C. difficile, JC virus, and S. aureus.

XBiotech operates pre-commercially with no approved or marketed products. Revenue history is dominated by a single transformative transaction: the December 2019 sale of bermekimab to Janssen Biotech for $750 million in cash upfront plus up to $600 million in potential milestone payments, with XBiotech retaining anti-IL-1α rights for non-dermatological indications. Capital sources have included ~$250M cumulative funding (seed through IPO), with the 2015 NASDAQ IPO via Dutch auction raising ~$76M and ongoing reliance on Swiss investor rounds and insider/major shareholder support (≥27% insider ownership). The company is funded to advance multiple Phase II programs but continues to report significant operating losses (most recently $0.88/share quarterly loss). Leadership transitioned in 2024–2025 from founder-CEO Simard to Interim CEO Sushma Shivaswamy, the former CSO. Future monetization depends on clinical readouts across vilamakitug, Natrunix, Hutrukin, and Unmetix, and on the ability to retain rights and build or partner a commercial launch capability in rheumatology, neurology, and infectious diseases.

Short descriptiontext

XBiotech is a clinical-stage biopharmaceutical company (NASDAQ: XBIT) developing True Human™ antibody therapies derived from natural donor immunity, with in-house GMP manufacturing and a pipeline spanning oncology, rheumatology, neurology, and infectious diseases. The company is pre-commercial with no approved products, funded historically by a $750M bermekimab sale to Janssen (2019) and a 2015 NASDAQ IPO.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic antibody development, biopharmaceutical drug development, monoclonal antibody therapies, clinical stage biotechnology, anti inflammatory biologics
Industry4 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutic Antibodies
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Acquisition Revenue
TypeLicensing Royalties
Description

XBiotech sold bermekimab (its IL-1α blocking True Human antibody) to Janssen in December 2019 for $750 million in upfront cash plus up to $600 million in potential milestone payments. As part of the agreement, XBiotech retained rights to develop True Human antibodies targeting IL-1α for non-dermatological indications.

xbiotech.com
2Therapeutic Antibody Development and Commercialization
TypeOne Time License
Description

Pre-commercial stage biopharmaceutical company developing a pipeline of True Human antibody therapeutic candidates. Revenue will be generated through eventual product sales following regulatory approval across multiple therapeutic areas including oncology, rheumatology, neurology, and infectious diseases.

xbiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1True Human™
Description

XBiotech's proprietary antibody discovery and development platform that derives therapeutic antibodies from natural human immunity

xbiotech.com
+4 more records
Core offering1 text field

XBiotech is a clinical-stage biopharmaceutical company that discovers, develops, and manufactures True Human™ monoclonal antibody therapies derived directly from natural human immunity rather than animal-derived or engineered sources. Its pipeline spans anti-inflammatory antibodies (anti-IL-1α) for oncology, rheumatology, and neurology indications, as well as infectious disease antibody candidates targeting shingles, C. difficile, influenza, S. aureus, and JC virus. The company operates fully integrated capabilities, including its proprietary SHSAM™ antibody mining platform, genetic cloning technology, and an in-house GMP manufacturing facility in Austin, Texas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Bermekimab acquired by Janssen for $750 million upfront plus up to $600M in milestones (2019)
+4 more records
Product overview1 text field

XBiotech is a fully integrated biopharmaceutical company developing True Human™ antibody therapies—a portfolio of distinct monoclonal antibody product candidates derived from natural human immunity rather than animal or engineered sources. The core platform combines Super High Stringency Antibody Mining (SHSAM™) technology with proprietary genetic cloning and an in-house GMP manufacturing platform. Key products include: vilamakitug (Phase II for axial spondyloarthritis), Natrunix (Phase II for rheumatoid arthritis), Hutrukin (Phase I for stroke), Unmetix (IND-stage for shingles), Bermekimab (sold to Janssen), plus infectious disease candidates targeting influenza, C. difficile, JC virus, and S. aureus. The company operates its own manufacturing facilities in Austin, Texas.

Product and service12 records
1Natrunix
CategoryTherapeutic antibody — anti-inflammatory
Description

True Human anti-IL-1α antibody candidate for rheumatoid arthritis that blocks interleukin-1α activity to reduce joint inflammation, tissue destruction, and pain; Phase II clinical study completed.

2Vilamakitug (PT064)
CategoryTherapeutic antibody — anti-inflammatory
Description

Next-generation True Human anti-IL-1α antibody in Phase II development for active axial spondyloarthritis (V-SPINE trial); derived from donors with natural human immunity and administered at 400mg via 16 weekly subcutaneous injections.

3Hutrukin
CategoryTherapeutic antibody — neurology
Description

True Human antibody candidate intended to reduce brain injury after stroke by limiting reperfusion injury when administered prior to clot-busting procedures; Phase I study completed.

4Unmetix™
CategoryTherapeutic antibody — infectious disease
Description

Combination antibody therapy (XB22-14 + XB2001/vilamakitug) for shingles and post-herpetic neuralgia; non-clinical data completed and IND submission planned.

5XB22-14
CategoryTherapeutic antibody — infectious disease
Description

True Human neutralizing antibody targeting varicella zoster virus, isolated from healthy donors with natural immunity; component of the Unmetix shingles therapy.

6C. difficile Therapeutic Antibody
CategoryTherapeutic antibody — infectious disease
Description

First-of-its-kind oral True Human antibody therapy for C. difficile intestinal infections that blocks bacterial motility and adhesion; manufacturing process development underway for oral delivery to the intestine.

7Influenza Antibody Candidates (IH201, IH302)
CategoryTherapeutic antibody — infectious disease
Description

True Human antibodies identified from genetic analysis of over a century of influenza viruses, capable of neutralizing all known influenza strains including the 1918 pandemic strain; master and working cell banks established.

8JC Virus Antibody
CategoryTherapeutic antibody — infectious disease
Description

True Human therapeutic candidate targeting JC virus, a human polyomavirus that causes progressive multifocal leukoencephalopathy (PML); donor antibody screening underway.

9Omodenbamab
CategoryTherapeutic antibody — infectious disease
Description

True Human antibody targeting S. aureus bacteremia that neutralizes bacteria including drug-resistant forms by reversing immune evasion mechanisms.

10Natrunix™ TASKIN Study
CategoryTherapeutic antibody — oncology
Description

Phase I/II clinical study combining Natrunix (1000mg) with trifluridine/tipiracil (FTD/TPI) and bevacizumab for metastatic colorectal cancer (mCRC); Phase II portion ongoing.

11True Human™ Antibody Platform
CategoryDiscovery and manufacturing platform
Description

Proprietary technology platform for discovering and developing therapeutic antibodies directly from natural human immunity, using SHSAM™ technology to identify rare, therapeutically relevant antibodies from blood donor samples.

12GMP Manufacturing Platform
CategoryManufacturing infrastructure / platform
Description

Fully integrated start-to-finish monoclonal antibody manufacturing platform at the Austin, Texas facility with single-use systems covering production cell banks through aseptic fill of vials and pre-filled syringes; clean rooms meet ISO 14644-1:2015 Class 7 and Class 5 standards.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Ongoing collaboration with UT Austin applying advanced microscopy imaging techniques to advance infectious disease pipeline. Publication in Journal of Microscopy (DOI: 10.1111/jmi.70038) highlighting work on C. difficile biofilms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collaboration with BioBridge Global (BBG), a major Texas blood bank, to analyze blood samples for COVID antibodies. BBG provided convalescent blood donations to XBiotech for development of True Human antibody therapeutics against COVID-19.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-12-01
Description

In December 2019, Janssen acquired bermekimab from XBiotech for $750 million in upfront cash plus up to $600 million in potential milestone payments. XBiotech retained rights to develop next-generation anti-IL-1α antibodies for non-dermatological indications. This was the largest biotech acquisition deal involving a Texas-based company at the time.

4Dr. Daniel Vasella
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Former CEO of Novartis joined XBiotech's board of directors. Named 'most Influential European Business Leader of the Last 25 Years' by Financial Times.

xbiotech.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

XBiotech

Biopharmaceutical Therapeutic Antibodiesxbiotech.com

XBiotech is a clinical-stage biopharmaceutical company (NASDAQ: XBIT) developing True Human™ antibody therapies derived from natural donor immunity, with in-house GMP manufacturing and a pipeline spanning oncology, rheumatology, neurology, and infectious diseases. The company is pre-commercial with no approved products, funded historically by a $750M bermekimab sale to Janssen (2019) and a 2015 NASDAQ IPO.

What XBiotech does

XBiotech (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company headquartered in Austin, Texas, founded in 2005 by John Simard to develop therapeutic antibodies derived directly from natural human immunity. Its True Human™ platform uses proprietary Super High Stringency Antibody Mining (SHSAM™) and genetic cloning technologies to identify rare, clinically relevant antibodies from blood donors — a position the company distinguishes from "humanized" or phage-display-derived antibodies — combined with a purpose-built, in-house single-use GMP bioreactor manufacturing facility (ISO Class 7/5 clean room) on a 48-acre Austin campus. The pipeline is centered on anti-IL-1α antibodies (vilamakitug in Phase II for axial spondyloarthritis; Natrunix in Phase II for rheumatoid arthritis and metastatic colorectal cancer via the TASKIN combination), plus Hutrukin (Phase I for stroke), Unmetix (anti-VZV + anti-IL-1α cocktail for shingles/PHN), and infectious-disease candidates targeting influenza, C. difficile, JC virus, and S. aureus.

XBiotech operates pre-commercially with no approved or marketed products. Revenue history is dominated by a single transformative transaction: the December 2019 sale of bermekimab to Janssen Biotech for $750 million in cash upfront plus up to $600 million in potential milestone payments, with XBiotech retaining anti-IL-1α rights for non-dermatological indications. Capital sources have included ~$250M cumulative funding (seed through IPO), with the 2015 NASDAQ IPO via Dutch auction raising ~$76M and ongoing reliance on Swiss investor rounds and insider/major shareholder support (≥27% insider ownership). The company is funded to advance multiple Phase II programs but continues to report significant operating losses (most recently $0.88/share quarterly loss). Leadership transitioned in 2024–2025 from founder-CEO Simard to Interim CEO Sushma Shivaswamy, the former CSO. Future monetization depends on clinical readouts across vilamakitug, Natrunix, Hutrukin, and Unmetix, and on the ability to retain rights and build or partner a commercial launch capability in rheumatology, neurology, and infectious diseases.

XBiotech firmographics

Firmographics
Name
XBiotech
Legal name
XBiotech USA, Inc.
Website
https://xbiotech.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
XBiotech is a clinical-stage biopharmaceutical company (NASDAQ: XBIT) developing True Human™ antibody therapies derived from natural donor immunity, with in-house GMP manufacturing and a pipeline spanning oncology, rheumatology, neurology, and infectious diseases. The company is pre-commercial with no approved products, funded historically by a $750M bermekimab sale to Janssen (2019) and a 2015 NASDAQ IPO.
Ownership category
akta.pro rank

XBiotech industry classification

Industry
Product category
Biopharmaceutical Therapeutic Antibodies
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Therapeutic antibody development
  • Biopharmaceutical drug development
  • Monoclonal antibody therapies
  • Clinical stage biotechnology
  • Anti inflammatory biologics

Where XBiotech is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices4 records

Markets served

XBiotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Licensing and Acquisition Revenue: XBiotech sold bermekimab (its IL-1α blocking True Human antibody) to Janssen in December 2019 for $750 million in upfront cash plus up to $600 million in potential milestone payments. As part of the agreement, XBiotech retained rights to develop True Human antibodies targeting IL-1α for non-dermatological indications.
  2. Therapeutic Antibody Development and Commercialization: Pre-commercial stage biopharmaceutical company developing a pipeline of True Human antibody therapeutic candidates. Revenue will be generated through eventual product sales following regulatory approval across multiple therapeutic areas including oncology, rheumatology, neurology, and infectious diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

XBiotech product offering

Product offering

Core offering

XBiotech is a clinical-stage biopharmaceutical company that discovers, develops, and manufactures True Human™ monoclonal antibody therapies derived directly from natural human immunity rather than animal-derived or engineered sources. Its pipeline spans anti-inflammatory antibodies (anti-IL-1α) for oncology, rheumatology, and neurology indications, as well as infectious disease antibody candidates targeting shingles, C. difficile, influenza, S. aureus, and JC virus. The company operates fully integrated capabilities, including its proprietary SHSAM™ antibody mining platform, genetic cloning technology, and an in-house GMP manufacturing facility in Austin, Texas.

Product overview

XBiotech is a fully integrated biopharmaceutical company developing True Human™ antibody therapies—a portfolio of distinct monoclonal antibody product candidates derived from natural human immunity rather than animal or engineered sources. The core platform combines Super High Stringency Antibody Mining (SHSAM™) technology with proprietary genetic cloning and an in-house GMP manufacturing platform. Key products include: vilamakitug (Phase II for axial spondyloarthritis), Natrunix (Phase II for rheumatoid arthritis), Hutrukin (Phase I for stroke), Unmetix (IND-stage for shingles), Bermekimab (sold to Janssen), plus infectious disease candidates targeting influenza, C. difficile, JC virus, and S. aureus. The company operates its own manufacturing facilities in Austin, Texas.

Differentiator

Problem solved

Functional benefit

Brands

  • True Human™: XBiotech's proprietary antibody discovery and development platform that derives therapeutic antibodies from natural human immunity
  • Natrunix™
  • Unmetix™
  • Hutrukin™
  • Natrunix™ Trifluridine/Tipiracil (TASKIN)

Products and services

  • Natrunix True Human anti-IL-1α antibody candidate for rheumatoid arthritis that blocks interleukin-1α activity to reduce joint inflammation, tissue destruction, and pain; Phase II clinical study completed.
  • Vilamakitug (PT064) Next-generation True Human anti-IL-1α antibody in Phase II development for active axial spondyloarthritis (V-SPINE trial); derived from donors with natural human immunity and administered at 400mg via 16 weekly subcutaneous injections.
  • Hutrukin True Human antibody candidate intended to reduce brain injury after stroke by limiting reperfusion injury when administered prior to clot-busting procedures; Phase I study completed.
  • Unmetix™ Combination antibody therapy (XB22-14 + XB2001/vilamakitug) for shingles and post-herpetic neuralgia; non-clinical data completed and IND submission planned.
  • XB22-14 True Human neutralizing antibody targeting varicella zoster virus, isolated from healthy donors with natural immunity; component of the Unmetix shingles therapy.
  • C. difficile Therapeutic Antibody First-of-its-kind oral True Human antibody therapy for C. difficile intestinal infections that blocks bacterial motility and adhesion; manufacturing process development underway for oral delivery to the intestine.
  • Influenza Antibody Candidates (IH201, IH302) True Human antibodies identified from genetic analysis of over a century of influenza viruses, capable of neutralizing all known influenza strains including the 1918 pandemic strain; master and working cell banks established.
  • JC Virus Antibody True Human therapeutic candidate targeting JC virus, a human polyomavirus that causes progressive multifocal leukoencephalopathy (PML); donor antibody screening underway.
  • Omodenbamab True Human antibody targeting S. aureus bacteremia that neutralizes bacteria including drug-resistant forms by reversing immune evasion mechanisms.
  • Natrunix™ TASKIN Study Phase I/II clinical study combining Natrunix (1000mg) with trifluridine/tipiracil (FTD/TPI) and bevacizumab for metastatic colorectal cancer (mCRC); Phase II portion ongoing.
  • True Human™ Antibody Platform Proprietary technology platform for discovering and developing therapeutic antibodies directly from natural human immunity, using SHSAM™ technology to identify rare, therapeutically relevant antibodies from blood donor samples.
  • GMP Manufacturing Platform Fully integrated start-to-finish monoclonal antibody manufacturing platform at the Austin, Texas facility with single-use systems covering production cell banks through aseptic fill of vials and pre-filled syringes; clean rooms meet ISO 14644-1:2015 Class 7 and Class 5 standards.

Quantifiable outcome

  • Bermekimab acquired by Janssen for $750 million upfront plus up to $600M in milestones (2019)
  • +4 more outcomes

Companies that use XBiotech

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles3 records

XBiotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

XBiotech partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

  • University of Texas at AustincoreStrategic or Co-development Partner · 1 February 2026Ongoing collaboration with UT Austin applying advanced microscopy imaging techniques to advance infectious disease pipeline. Publication in Journal of Microscopy (DOI: 10.1111/jmi.70038) highlighting work on C. difficile biofilms.
  • BioBridge GlobalcoreStrategic or Co-development Partner · 1 January 2020Collaboration with BioBridge Global (BBG), a major Texas blood bank, to analyze blood samples for COVID antibodies. BBG provided convalescent blood donations to XBiotech for development of True Human antibody therapeutics against COVID-19.
  • Janssen Biotech (Johnson & Johnson)flagshipOEM/ Whitelabel/ Licensing Partner · 1 December 2019In December 2019, Janssen acquired bermekimab from XBiotech for $750 million in upfront cash plus up to $600 million in potential milestone payments. XBiotech retained rights to develop next-generation anti-IL-1α antibodies for non-dermatological indications. This was the largest biotech acquisition deal involving a Texas-based company at the time.
  • Dr. Daniel VasellaminorStrategic or Co-development Partner · 1 January 2015Former CEO of Novartis joined XBiotech's board of directors. Named 'most Influential European Business Leader of the Last 25 Years' by Financial Times.

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

XBiotech competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

XBiotech social profiles

Digital presence

XBiotech compliance and trust

Trust signal

Compliance2 records

XBiotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

XBiotech leadership team

Management profile

Number of profiles

Profiles5 records

XBiotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

XBiotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XBiotech

What does XBiotech do?

XBiotech is a clinical-stage biopharmaceutical company that discovers, develops, and manufactures True Human™ monoclonal antibody therapies derived directly from natural human immunity rather than animal-derived or engineered sources. Its pipeline spans anti-inflammatory antibodies (anti-IL-1α) for oncology, rheumatology, and neurology indications, as well as infectious disease antibody candidates targeting shingles, C. difficile, influenza, S. aureus, and JC virus. The company operates fully integrated capabilities, including its proprietary SHSAM™ antibody mining platform, genetic cloning technology, and an in-house GMP manufacturing facility in Austin, Texas.

Is XBiotech a public or private company?

XBiotech is a public company. It is classified as public and is currently operating.

When was XBiotech founded?

XBiotech was founded in 2005. It employs 51 to 100 people.

Where is XBiotech based?

XBiotech is headquartered in Austin, United States, in the North America region.

How does XBiotech make money?

Two revenue lines are on record. Licensing and Acquisition Revenue is the primary driver. The others are therapeutic Antibody Development and Commercialization.

Does XBiotech have an API?

No public API is recorded for XBiotech.

What industry is XBiotech in?

XBiotech's product category is Biopharmaceutical Therapeutic Antibodies. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingXBiotech Files Initial Beneficial Ownership Statement for Co-CEO Jan-Paul SimardXBiotech's co-CEO Jan-Paul Simard filed an initial beneficial ownership statement covering an October 23, 2026 reporting event. The filing was published via EDGAR on October 28, 2026, and is for informational purposes only.TradingViewXBiotech 10% Owner Purchased Shares Worth Over $711KJohn Simard, a 10% owner and director of XBiotech, purchased 368,524 shares at $1.93 per share for $711,251. The transaction, filed with the SEC, left him directly owning 4,191,690 shares.TradingViewXBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOsXBiotech appointed Dr. Sushma Shivaswamy and Jan-Paul Simard as co-CEOs, effective October 23, 2026. Shivaswamy continues as CSO and earns $750,000 annually, while Simard receives a $150,000 base salary and 2 million stock options. The appointment is not disclosed as a reason.FinanzNachrichten.deXBiotech Inc.: XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekanntXBiotech's board selected Jan-Paul Simard as Co-Chief Executive Officer effective October 23, 2026, alongside CEO Dr. Sushma Shivaswamy. Simard, who joined in 2012, brings operational continuity, while Shivaswamy, interim CEO since December 2025, will lead the company's True-Human antibody therapies.Quiver QuantitativeXBiotech Appoints Jan-Paul Simard as Co-Chief Executive Officer Alongside Dr. Sushma Shivaswamy | XBIT Stock NewsXBiotech appointed Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. Dr. Shivaswamy has served as interim CEO since December 2025, and Simard brings clinical development experience. The company aims to advance its True-Human antibody therapies.FinanzNachrichten.deXBiotech Inc.: XBiotech gibt positive endgültige Wirksamkeitsergebnisse der Phase-II-Studie "TASKIN" bekannt, einer von Forschern initiierten Studie zur Behandlung von refraktärem metastasiertem KolorXBiotech announced positive final efficacy results from its Phase-II TASKIN study for refractory metastatic colorectal cancer. The study met its primary endpoint with a 12-month overall survival rate of 61.3% versus 55.7% in the control group. An exploratory analysis showed a 62% reduction in death risk for patients with right-sided tumors.GlobeNewswireXBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaireXBiotech announced positive final efficacy results for phase II of the TASKIN trial, where vilamakitug added to standard therapy improved 12-month overall survival to 61.3% versus 55.7% in placebo. A subgroup analysis showed a significant survival benefit for right-sided colon tumors, with a 62% reduction in death risk.The future of tradingXBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal CancerXBiotech announced positive Phase II results from the TASKIN trial in refractory metastatic colorectal cancer, meeting its primary efficacy criterion. At 12 months, 61.3% of patients in the vilamakitug arm were alive versus 55.7% in the control arm. An exploratory analysis showed a significant survival benefit in right-sided tumors.Ticker ReportFinancial Comparison: Nanobiotix (NASDAQ:NBTX) versus XBiotech (NASDAQ:XBIT)MarketBeat conducted a comparative financial analysis of healthcare companies XBiotech and Nanobiotix, evaluating metrics including earnings, valuation, institutional ownership, and analyst recommendations. The report concluded that Nanobiotix outperformed XBiotech on seven of the ten compared factors, citing stronger consensus ratings and higher probable upside despite both companies reporting net losses.Clinical Trials ArenaXBiotech to commence V-SPINE trial enrolment for vilamakitugXBiotech will start enrolment for the V-SPINE Phase II trial of vilamakitug in adults with active axial spondyloarthritis, following FDA NDA clearance. The placebo-controlled trial randomizes 150 patients to 400mg injections or placebo, with ASAS40 as the primary endpoint. A 12-week open-label extension will follow.